Indivior Lifts 2026 Outlook as Record SUBLOCADE Sales Drive Q2 Net Income to $122M
INDV has more than doubled off its 52-week low of $19.31.
Summary
Indivior posted record Q2 2026 results fueled by 21% SUBLOCADE growth, raised its full-year guidance, and highlighted $175M in share repurchases—all on the same day it announced a merger of equals with Supernus.
Key Events · Earnings and Guidance · INDV
-
Record SUBLOCADE Revenue Drives Beat
Q2 2026 SUBLOCADE net revenue reached $253M (+21% YoY), pushing total net revenue to $343M (+14% YoY). U.S. SUBLOCADE dispense units grew 18%, with record new patient starts of 32,816.
-
Profitability Surge
GAAP net income was $122M ($0.98 diluted EPS) vs. $18M a year ago. Adjusted EBITDA more than doubled to $186M, with margin expanding to 54% from 29%.
-
Full-Year Guidance Raised
2026 total net revenue guidance raised to $1.295B–$1.365B (midpoint +$80M), SUBLOCADE to $1.010B–$1.050B (midpoint +$60M), and adjusted EBITDA to $700M–$740M (midpoint +$80M).
-
Aggressive Share Buybacks
Repurchased $175M in shares during Q2 (4.7M shares at avg $37.52), bringing YTD total to $300M (8.6M shares at avg $34.73). Cash and investments stood at $249M as of June 30.
Analysis · INDV · Life Sciences
A standout quarter saw SUBLOCADE net revenue climb 21% year-over-year to a record $253 million, lifting total revenue 14% to $343 million. The operating leverage was dramatic: GAAP net income surged to $122 million from $18 million a year ago, while adjusted EBITDA more than doubled to $186 million. Reflecting this momentum, management raised full-year guidance across the board—now projecting SUBLOCADE revenue of $1.01–$1.05 billion and adjusted EBITDA of $700–$740 million. The company also repurchased $175 million in shares during the quarter. These results, released alongside the announced merger with Supernus, underscore Indivior's financial strength heading into the combination.
At the time of this filing, INDV was trading at $41.56 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.9B. The 52-week trading range was $19.31 to $42.81. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.